LSBCF (LakeShore Biopharma Co) Shares Buyback Ratio %: -9.17 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is LakeShore Biopharma Co Shares Buyback Ratio %?

LakeShore Biopharma Co LSBCF Shares Buyback Ratio % is -9.17 as of Jul. 22, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. LakeShore Biopharma Co's current shares buyback ratio was -9.17%.

LakeShore Biopharma Co Shares Buyback Ratio % Related Terms

LakeShore Biopharma Co Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Shares Buyback Ratio % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Shares Buyback Ratio %
0.00 0.00 -0.97 -104.42 -9.17

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only -0.97 0.00 -104.42 -0.30 -8.84

LakeShore Biopharma Co Shares Buyback Ratio % Calculation

LakeShore Biopharma Co's Shares Buyback Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2024 ) - Shares Outstanding (EOP) (A: Mar. 2025 )) / Shares Outstanding (EOP) (A: Mar. 2024 )
=(19.023 - 20.767) / 19.023
=-9.17%

LakeShore Biopharma Co's Shares Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2024 ) - Shares Outstanding (EOP) (A: Mar. 2025 )) / Shares Outstanding (EOP) (A: Sep. 2024 )
=(19.081 - 20.767) / 19.081
=-8.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -9.17 mean?
LakeShore Biopharma Co (LSBCF) has a Shares Buyback Ratio % of -9.17 as of Jul. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Shares Buyback Ratio % too high?
LakeShore Biopharma Co's current Shares Buyback Ratio % is -9.17.
How does LakeShore Biopharma Co's Shares Buyback Ratio % compare to ACUT and PPCB?
LakeShore Biopharma Co's Shares Buyback Ratio % of -9.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Shares Buyback Ratio % is -9.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Shares Buyback Ratio % of -9.17. The current Shares Buyback Ratio % is -9.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Shares Buyback Ratio % is -9.17 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.